RESP-X successfully completes Phase I trial and initiates Phase IIa trial in NCFB patients
No adverse events reported across all cohorts
Approval for dosing final RESP-X Phase Ia cohort and first-in-patient Phase IIa
RESP-X continues to exhibit strong safety and tolerability profile
Clinical candidate nominated for COV-X programme
COV-X is a novel first-in-class small molecule oral pan-coronavirus antiviral candidate
Podcast: Will A ‘Netflix’ Model Solve Antibiotic Reimbursement Challenges And Spur R&D?
Infex CEO Peter Jackson discusses the state of antimicrobial resistance in the UK, and globally. He highlights the potential of a new…
Interim results demonstrate a favourable safety and tolerability profile for RESP-X in ongoing Phase I clinical trial
Accelerates plans for Phase IIa study
Infex strengthens Board with appointment of Professor Colm Leonard as Non-Executive Director
Infex Therapeutics is pleased to announce the appointment of Professor Colm Leonard as a Non-Executive Director of Infex with immediate…
Antimicrobial discovery and drug development – RSC Podcast
How do we develop drugs like antibiotics? How long does it take for such a drug to go from its inception in a research lab to use in a…
Infex’s novel AMR drug candidate MET-X receives FDA QIDP designation
This designation gives MET-X an accelerated U.S. regulatory pathway and an additional five-years of market exclusivity upon approval.
Infex enters clinic with lead anti-virulence candidate RESP-X for Pseudomonas aeruginosa
Infex Therapeutics, a leading anti-infectives specialist, is pleased to announce the first subjects have been dosed in Phase I study in…
Infex Awarded Biomedical Catalyst Grant For COV-X Project
Infex Therapeutics, a leading anti-infectives specialist, is delighted to announce a successful grant award of £850,000 to support its 18…